Erschienen in:
01.10.2014
Serum Ficolin-2 in Hospitalised Patients with Community-Acquired Pneumonia
verfasst von:
James D. Chalmers, Gilly B. Fleming, Julia Rutherford, Misao Matsushita, David C. Kilpatrick, Adam T. Hill
Erschienen in:
Inflammation
|
Ausgabe 5/2014
Einloggen, um Zugang zu erhalten
Abstract
Mannose binding lectin (MBL) and ficolins contribute to host defence through activation of the lectin pathway of complement. In this study, serum levels of ficolin-2 and MBL were determined in 276 patients with community-acquired pneumonia (CAP). MBL deficiency and ficolin-2 insufficiency were defined using previously validated cut-offs. No differences were observed in MBL or ficolin-2 between patients and controls. MBL-deficient patients (<500 ng/ml) were not at higher risk of 30-day mortality odds ratio (OR) 0.97 (0.38–2.48,p = 0.9) or a composite outcome of mortality, mechanical ventilation, vasopressor support (MV/VS) or complications OR 0.89 (0.44–1.77, p = 0.9). Although no significant relationship between ficolin-2 insufficiency and outcome was observed, very low ficolin-2 levels (<1,200 ng/ml) were associated with an OR 1.23 (0.15–10.1), p = 0.6 for 30-day mortality, 3.05 (0.61–15.2, p = 0.2) for MV/VS and OR 2.05 (0.52–8.1, p = 0.2) for the composite outcome. Low serum levels of MBL and ficolin-2 are not associated with CAP susceptibility. The high frequency of ficolin-2 insufficiency in patients with severe CAP would justify a larger investigation of ficolin-2 as a modifier of CAP severity.